Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients Registries in Rheumatological and Musculoskeletal Conditions

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 50; no. 1; pp. 189 - 195
Main Authors SOUTHWOOD, Taunton R, FOSTER, Helen E, RHEUMATOLOGY BIOLOGICS, Paediatric, REGISTER, New Drugs, DAVIDSON, Joyce E, HYRICH, Kimme L, COTTER, Catherine B, WEDDERBURN, Lucy R, HULL, Richard G, VENNING, Helen E, RAHMAN, Joy K, CUMMINS, Carole L
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 2011
Subjects
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Diseases of the osteoarticular system
Immunomodulators
Inflammatory joint diseases
Medical sciences
Pharmacology. Drug treatments
Antineoplastic agent
Human
Toxicity
Diseases of the osteoarticular system
Antipsoriatic agent
Rheumatology
Juvenile rheumatoid arthritis
Inflammatory joint disease
Duration
Arthritis
Juvenile idiopathic arthritis
Immunomodulator
Drug discontinuations
Chronic
Treatment
Etanercept
Serious adverse event
Secondary effect
Remission
Antirheumatic agent
Disease remission
Methotrexate
Child
Online AccessGet full text

Cover

More Information
ISSN:1462-0324
1462-0332